
|Videos|May 30, 2017
Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer
Author(s)Hope S. Rugo, MD
Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































